Afinitor and Spinal cord neoplasm - a phase IV clinical study of FDA data

Summary:

Spinal cord neoplasm is reported as a side effect among people who take Afinitor (everolimus), especially for people who are male, 50-59 old, also take Lenvatinib, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Spinal cord neoplasm when taking Afinitor. It is created by eHealthMe based on reports of 41,609 people who have side effects when taking Afinitor from the FDA, and is updated regularly.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

What is Spinal cord neoplasm?

Spinal cord neoplasm (tumour of spinal cord) is found to be associated with 144 drugs and 192 conditions by eHealthMe. Check the latest studies of Spinal cord neoplasm.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

41,609 people reported to have side effects when taking Afinitor.
Among them, 15 people (0.04%) have Spinal cord neoplasm.

Could Afinitor cause Spinal cord neoplasm?

Among these 15 people:

What is the gender of people who have Spinal cord neoplasm when taking Afinitor? *

female: 20 %
male: 80 %

What is the age of people who have Spinal cord neoplasm when taking Afinitor? *

What are other drugs people take besides Afinitor? *

What are other side effects people have besides Spinal cord neoplasm? *

Constipation: 3 people, 20.00%
Second Primary Malignancy (after getting cure a cancer, a new cancer development): 3 people, 20.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 2 people, 13.33%
Hypoaesthesia (reduced sense of touch or sensation): 2 people, 13.33%
Muscle Function Loss: 2 people, 13.33%
Hepatic Enzyme Increased: 2 people, 13.33%
Nosebleed (bleeding from nose): 2 people, 13.33%
Gait Disturbance: 2 people, 13.33%
Fever: 2 people, 13.33%
Pain: 2 people, 13.33%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 3 people, 20.00%
Neuroendocrine Tumor: 2 people, 13.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 6.67%
Renal Cell Carcinoma Stage Iv (stage iv renal cell cancer have cancer that has spread to other organs, such as the lungs, liver, bones, or brain, and may have spread to lymph nodes): 1 person, 6.67%
Pancreatic Neuroendocrine Tumor Metastatic: 1 person, 6.67%
Pancreatic Neuroendocrine Tumor: 1 person, 6.67%
Metastases To Bone (cancer spreads to bone): 1 person, 6.67%
Carcinoid Tumor: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Afinitor and have Spinal cord neoplasm?

- Check whether Spinal cord neoplasm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Afinitor:

Afinitor (41,680 reports)

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Spinal cord neoplasm:

Spinal cord neoplasm (144 drugs)

Browse all the conditions that are associated with Spinal cord neoplasm:

Spinal cord neoplasm (192 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.